Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF
The half-life of recombinant human von Willebrand factor (rVWF) expressed in CHO cells (CHO-rVWF; Vonicog alfa; and Vonvendi/Veyvondi) is significantly longer than that of plasma-derived VWF (pdVWF). This finding is intriguing because CHO cells do not generate α2-6 sialylation, which constitutes the majority of human pdVWF sialylation. We hypothesized that glycan differences might regulate the longer half-life of CHO-rVWF. In lectin plate-binding assays and liquid chromatography-mass spectrometry analysis, we confirmed that CHO-rVWF lacked α2-6-linked sialylation. Conversely, however, α2-3-linked sialylation was significantly increased on CHO-rVWF, which also had reduced exposed β-galactose (β-Gal) compared to pdVWF. Consistent with human data, CHO-rVWF clearance was significantly (P < .001) reduced in VWF-/- mice compared to pdVWF. However, clearance of asialo-pdVWF and asialo-CHO-rVWF were identical. In keeping with the in vivo half-life prolongation, CHO-rVWF binding to murine macrophages (P = .012) and HepG2 cells (P = .001) was significantly decreased compared to pdVWF. Furthermore, CHO-rVWF binding to purified macrophage-galactose-type lectin (MGL) receptor and asialoglycoprotein receptor (ASGPR) was also significantly reduced. In contrast to pdVWF, in vivo studies in MGL1-/- mice and Asgr1-/- mice demonstrated that neither MGL nor ASGPR plays significant roles in regulating CHO-rVWF clearance. Together, our findings demonstrate that enhanced α2-3-linked sialylation on CHO-rVWF is responsible for its extended half-life.
Authors
- Ciara Byrne (ORCID: https://orcid.org/0000-0003-3332-0644)
- James S. O’Donnell (ORCID: https://orcid.org/0000-0003-0309-3313)
- Daniel I. R. Spencer (ORCID: https://orcid.org/0000-0001-6386-0890)
- Alain Chion
- Roger J. S. Preston (ORCID: https://orcid.org/0000-0003-0108-4077)
- Ross Baker (ORCID: https://orcid.org/0000-0002-2728-6788)
- Marco P. Monopoli (ORCID: https://orcid.org/0000-0002-2035-6894)
- Peter L. Turecek (ORCID: https://orcid.org/0000-0002-6161-1556)
- Jack Cheeseman (ORCID: https://orcid.org/0000-0003-1112-217X)
- Maximilianos Kotsias (ORCID: https://orcid.org/0000-0002-3417-782X)
- Ferdows Atiq (ORCID: https://orcid.org/0000-0002-3769-9148)
- Richard A. Gardner (ORCID: https://orcid.org/0000-0001-7601-7544)
- Patricia Lopes (ORCID: https://orcid.org/0000-0001-9287-5354)
- Jamie M. O’Sullivan (ORCID: https://orcid.org/0000-0002-1162-8739)
- Soracha E. Ward (ORCID: https://orcid.org/0000-0003-1730-8485)
- Alan B. Moran (ORCID: https://orcid.org/0000-0003-4150-3942)
- Bogdan Baci
- Caoimhe Dowd
- Darragh Jordan
Institutions
- Royal College of Surgeons in Ireland (IE)
- Murdoch University (AU)
- Culham Science Centre (GB)
- Netherlands Metabolomics Centre (NL)
- Irish Blood Transfusion Service (IE)
- St. James's Hospital (IE)
- Takeda (Austria) (AT)
- Ludger (United Kingdom) (GB)
Publication Details
- Journal
- Blood
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1182/blood.2024027038
- Citations
- 3
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 2.42